These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 8101237)

  • 1. [Vasodilator therapy in cardiac failure].
    Akatsuka N
    Nihon Rinsho; 1993 May; 51(5):1276-80. PubMed ID: 8101237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
    Cohn JN; Archibald DG; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Francis GS; Flohr KH
    N Engl J Med; 1986 Jun; 314(24):1547-52. PubMed ID: 3520315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R; Kunstmann S; Jalil J
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
    Cohn JN
    Herz; 1991 Sep; 16 Spec No 1():267-71. PubMed ID: 1820292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
    Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Modern vasodilator medication in refractory cardiac insufficiency].
    Stanciu L; Branea I; Riviş I; Radivoievici A; Mancaş S; Păunescu A
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(2):129-34. PubMed ID: 6139858
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
    Johnson G; Carson P; Francis GS; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI32-9. PubMed ID: 8500237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
    Gogia H; Mehra A; Parikh S; Raman M; Ajit-Uppal J; Johnson JV; Elkayam U
    J Am Coll Cardiol; 1995 Dec; 26(7):1575-80. PubMed ID: 7594088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afterload reduction in the treatment of cardiac failure.
    Mason DT
    Schweiz Med Wochenschr; 1978 Nov; 108(44):1695-703. PubMed ID: 102028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition.
    Verma SP; Silke B; Reynolds GW; Kelly JG; Richmond A; Taylor SH
    J Cardiovasc Pharmacol; 1992 Aug; 20(2):274-81. PubMed ID: 1381019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiac failure and nitrates].
    Galinier M; Bounhoure JP
    Ann Cardiol Angeiol (Paris); 1997; 46(7):415-9. PubMed ID: 9452775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
    Massie B; Chatterjee K; Werner J; Greenberg B; Hart R; Parmley WW
    Am J Cardiol; 1977 Nov; 40(5):794-801. PubMed ID: 411364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
    Chatterjee K; Massie B; Rubin S; Gelberg H; Brundage BH; Ports TA
    Am J Med; 1978 Jul; 65(1):134-45. PubMed ID: 99031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
    Goldman S; Johnson G; Cohn JN; Cintron G; Smith R; Francis G
    Circulation; 1993 Jun; 87(6 Suppl):VI24-31. PubMed ID: 8500236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of cardiac failure with vasodilators (author's transl)].
    Imhof P
    Schweiz Rundsch Med Prax; 1978 May; 67(22):219-29. PubMed ID: 418395
    [No Abstract]   [Full Text] [Related]  

  • 19. [Vasodilator agents in the treatment of heart failure].
    Prati PL; Manfrin M
    G Ital Cardiol; 1978; 8(1):1-11. PubMed ID: 415927
    [No Abstract]   [Full Text] [Related]  

  • 20. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.